A disease area unit within a global biopharmaceutical company was charged with a mandate to seek out novel candidate assets in development to treat inflammatory bowel disease (IBD) and Celiac disease After a thorough internal review of the public biotech landscape, Alacrita was contacted to assist in their search and evaluation efforts for external innovation in all modalities, especially microbiome and tolerance induction, but not cell therapies. The stage of development of most interest to the client was primarily candidate stage assets within 18 months of an Investigational New Drug (IND) Application in the US and EU.
Alacrita consultants worked closely with the client to identify a stream of opportunities for further evaluation. An initial search of a commercial pipeline database was conducted focused on the client’s search criteria. Potential candidate assets were highlighted for the client and approved by in-house scientific team leaders for outreach. Non-confidential slide decks were requested from asset owners and further evaluated by Alacrita prior to determining whether to send to the client, depending on continued fit with the client’s search criteria. In parallel, secondary searches of technology licensing office and SBIR grant databases, as well as biotech incubators and venture capital portfolio companies were initiated. Over the three-month scouting campaign, >2,000 asset opportunities were evaluated and the client was provided with over 100 assets to approve for outreach, culminating in several attractive opportunities for further partnering discussions.
We regularly consult with clients developing therapeutics targeting digestive and GI diseases, as well as advise investors and BD teams on individual assets, pipelines and companies in this field. For more details on our expertise, please visit the below page or reach out.
Alacrita supports both large pharma and biotech companies with their search and evaluation activities. Our asset scouting support is often structured to integrate with the client’s internal efforts, resulting in a constant flow of new opportunities.